Willow Biosciences Inc. announce that it is undertaking two initiatives to help company customers evaluate and better understand cannabigerol ("CBG"), company first commercial cannabinoid slated for production in First Quarter 2021. Willow has engaged Signum Biosciences, a leading biopharmaceutical company focused on the discovery and development of innovative consumer products, to generate a robust safety and data package for company CBG to demonstrate its safety and activity as a cosmetic ingredient. The Company has also engaged a world-renowned regulatory consulting group to perform a comprehensive safety assessment to independently conclude that company CBG is Generally Regarded As Safe (GRAS) for use as an ingredient in food and beverage products and support future novel food submissions in multiple jurisdictions.